Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells

mTOR signaling and drug development in cancer

(2010) Janet Dancey   Nature Reviews Clinical Oncology

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

(2009) M Campone et al.   BRITISH JOURNAL OF CANCER

An Amino Acid Shuffle Activates mTORC1

(2009) Adiel Cohen et al.   CELL

High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma

(2009) V. K. Anagnostou et al.   CLINICAL CANCER RESEARCH

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Sirolimus Ameliorated Post Lung Transplant Chylothorax in Lymphangioleiomyomatosis

(2008) Toshiaki Ohara et al.   ANNALS OF THORACIC SURGERY

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas

(2008) Yoh Dobashi et al.   CANCER

Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer

(2008) Y. Yatabe et al.   CANCER RESEARCH

The Role of Targeting Mammalian Target of Rapamycin in Lung Cancer

(2008) Sumanta Kumar Pal et al.   Clinical Lung Cancer

Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

(2008) Brian M. Wolpin et al.   JOURNAL OF CLINICAL ONCOLOGY